Skip to Content
Merck

Distribution of cancer stem cells in two human brain gliomas.

Oncology letters (2019-02-06)
Lilei Peng, Jie Fu, Weijun Wang, Florence M Hofman, Thomas C Chen, Ligang Chen
ABSTRACT

There is compelling evidence that brain tumors, particularly glioblastoma multiforme (GBM), harbor a small population of cancer stem cells (CSCs). These CSCs have the ability to undergo self-renewal, initiate tumors in vivo, and are resistant to chemotherapy and radiation therapy. The present study determined the spatial distribution of CSCs within the donated brains of two deceased patients affected by glioblastoma multiforme. The following six grossly visible functional regions were identified: Necrotic tumor, viable solid tumor, infiltrating tumor edge, peritumoral normal brain, normal brain close to the tumor and normal brain distant from the tumor. Each region was snap-frozen, sectioned and immunostained for the CSC biomarkers prominin-1 (CD133) and sex-determining region Y-box 2 (SOX2). The percentages of CD133+ and SOX2+ cells within each region were determined. Different percentages of CD133+ and SOX2+ cells were identified in different regions. Significantly higher percentages of CD133+ and SOX2+ cells were indicated at the infiltrating tumor edge when compared with other areas. In summary, the spatial distributions of CSCs in these two brains with glioblastoma multiforme were similar, with the highest concentration being at the infiltrating tumor edge. This suggests that the edge of the tumor is the moving front for tumor progression and invasion, and should be targeted for therapeutic intervention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CD133 Antibody, clone 13A4, clone 13A4, Chemicon®, from rat
Sigma-Aldrich
Monoclonal Anti-SOX2 antibody produced in mouse, clone 10F10, ascites fluid
Sigma-Aldrich
Mouse IgG1 Negative Control Antibody, clone 1E2.2, clone 1E2.2, 1 mg/mL, Chemicon®